Proteinopathies associated to repeat expansion disorders
- PMID: 35067760
- DOI: 10.1007/s00702-021-02454-5
Proteinopathies associated to repeat expansion disorders
Abstract
The most common neurodegenerative disorders, such as Alzheimer's or Parkinson's diseases, are characterized by synaptic dysfunction, neuronal loss and proteinaceous aggregates in central nervous system. The deposition of misfolded proteins constitutes neuropathological hallmarks of these diseases, grouped in the generic term of proteinopathies. Apart from these, other neurodegenerative diseases are characterized by genetic abnormalities like unstable repetitive simple sequence tracts (microsatellites) dispersed throughout the human genome. They are called repeat expansion disorders and include, for example, Huntington's disease or frontotemporal dementia/amyotrophic lateral sclerosis phenotypes associated to an expansion in C9ORF72. The presence of the expanded DNA tract leads to molecular alterations at the DNA, RNA and protein levels associated to distinct mechanisms, such as loss-of-function (LOF), gain-of-function (GOF) including misfolding of physiological or mutant proteins, favoring their polymerization and aggregation. Therefore, specific proteinopathies also arise from these repeat expansion disorders. The molecular description of the nature and location of expanded tracts, highlighting the consequences onto clinical phenotypes will be first described. Specific focuses on the three pathomechanisms of the repeat expansions associated to proteinopathies will then be addressed. Lastly, we will show how progress in the understanding of these different mechanisms has led to recent advances in new/innovative therapeutic approaches and emergence of associated biomarkers.
Keywords: Disease-modifying therapies; Neurodegenerative disorders; Polyglutamine diseases; Proteinopathies; RAN translation; Repeat expansions diseases.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
References
-
- Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, Sims J, Sperling RA, Vellas B (2020) The future of anti-amyloid trials. J Prev Alzheimer’s Dis 7(3):146–151. https://doi.org/10.14283/jpad.2020.24 - DOI
-
- Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobagyi T, Shaw CE (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 122(6):691–702. https://doi.org/10.1007/s00401-011-0911-2 - DOI - PubMed
-
- Ayhan F, Perez BA, Shorrock HK, Zu T, Banez-Coronel M, Reid T, Furuya H, Clark HB, Troncoso JC, Ross CA, Subramony SH, Ashizawa T, Wang ET, Yachnis AT, Ranum LP (2018) SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIFF. EMBO J https://doi.org/10.15252/embj.201899023
-
- Aziz NA, van Belzen MJ, Coops ID, Belfroid RD, Roos RA (2011) Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington’s disease. Eur J Med Genet 54(4):e413-418. https://doi.org/10.1016/j.ejmg.2011.04.002 - DOI - PubMed
-
- Bakkar N, Boehringer A, Bowser R (2015) Use of biomarkers in ALS drug development and clinical trials. Brain Res 1607:94–107. https://doi.org/10.1016/j.brainres.2014.10.031 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous

